Kodiak Sciences’ Tarcocimab Meets Noninferiority Endpoint Versus Aflibercept in Phase 3 DAYBREAK Trial in Wet AMD

Kodiak Sciences announced on 28 September 2026 that Zenkuda (tarcocimab tedromer), an investigational anti-vascular endothelial growth factor (VEGF) therapy, met the primary endpoint of its pivotal Phase 3 DAYBREAK trial in neovascular age-related macular degeneration (wet AMD): noninferiority to aflibercept in best-corrected visual acuity (BCVA) at one year. Of patients receiving tarcocimab, 54% were maintained on a 24-week treatment interval. That figure describes patients who reached the interval under the trial’s treatment algorithm and does not indicate how many would qualify for twice-yearly injections in routine practice.

DAYBREAK Results

• Product: Zenkuda (tarcocimab tedromer), designed to provide sustained disease control with fewer intravitreal injections.
• Comparator: Aflibercept.
• Primary endpoint: Noninferiority in BCVA at one year; met.
• Dosing interval: 54% of tarcocimab patients maintained on a 24-week interval.
• Second investigational arm: Tabirafusp-ted, a separate Kodiak program, also met the one-year noninferiority endpoint against aflibercept, according to the company.
• Safety: No intraocular inflammation reported in the Zenkuda arm.
• Presentation: Charles Wykoff, MD, PhD, at Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2026 Annual Meeting, New Orleans.

Clinicians will need arm-specific visual gains, anatomic results and adverse events before treating the two products as interchangeable. The absence of intraocular inflammation in the Zenkuda arm is reassuring; its weight depends on the size and duration of the safety database.

Reading the 24-Week Figure

Trial eligibility, loading doses, visit frequency and rescue criteria can make the interval achieved in a trial differ from a real-world schedule. The more useful clinical measures are how many patients maintained both visual acuity and a dry, stable retina after extension, and how quickly the protocol shortened treatment when fluid or vision changed.

Why Treatment Durability Matters

Wet AMD is a leading cause of severe vision impairment among older adults. Anti-VEGF treatments have transformed its management, yet many patients require frequent injections and continuous monitoring, which strains adherence, clinic capacity, patient mobility and caregiver support.

A longer interval has value when it preserves vision without adding unscheduled visits, rescue injections or close surveillance. Retina practices should therefore compare the total number of treatment and monitoring encounters. Outcomes among previously treated patients and those with persistent fluid also matter, because these patients may respond differently from treatment-naive trial participants.

Regulatory and Market Outlook

Kodiak has indicated plans to submit a multi-indication Biologics License Application (BLA) in the fourth quarter of 2026. Aflibercept and faricimab have already moved the treatment landscape toward longer dosing intervals, so competition will center on sustained efficacy, real-world durability, safety, treatment flexibility and overall clinical burden.

If approved, Zenkuda’s commercial case will rest on reproducible durability, flexible retreatment, reimbursement and clinician confidence in safety over repeated years. The forthcoming full dataset and the regulatory review will carry more weight than the headline 24-week percentage.

Conclusion

The 24-week interval is Kodiak’s central commercial claim. The clinically decisive measure is whether patients maintain vision with fewer total visits and little rescue treatment after extension. Full arm-level safety data and longer follow-up should guide any comparison with established anti-VEGF regimens.

Source: Kodiak Sciences, Phase 3 DAYBREAK announcement, 28 September 2026. https://ir.kodiak.com/news-releases/news-release-details/zenkuda-and-tabirafusp-ted-meet-primary-endpoints-pivotal

The post Kodiak Sciences’ Tarcocimab Meets Noninferiority Endpoint Versus Aflibercept in Phase 3 DAYBREAK Trial in Wet AMD appeared first on Ophthalmology Breaking News.

Source: ophthalmologybreakingnews.com
Author: OBN Editorial Team | Date: 2026-09-28 09:00:00